47 results about "Cotinine" patented technology

The invention discloses a synchronous analysis method for trace nicotine in blood-brain samples of an animal and main metabolites thereof. The synchronous analysis method is characterized by comprising the following steps of: utilizing a microdialysis system to synchronously collect blood dialysate and brain tissue dialysate samples of an animal in lined pipes of different chromatographic sampling bottles, respectively adding NIC-d3 and COT-d3 to be mixed with internal labeled solution, and after mixing uniformly, directly analyzing and detecting the content of the nicotine and cotinine in a microdialysis sample by using UPLC-MS/MS. The synchronous analysis method disclosed by the invention has the advantages that the pretreatment steps of protein precipitation and purification for the samples are not needed, the synchronous and accurate analysis of nicotine and metabolites in an animal body is realized; and compared with the prior art, the synchronous analysis method has the characteristics of simple operation, high sensitivity and reliable result and the like, and a new method for researching the metabolism of the nicotine in the animal body is provided.

The invention provides a burley tobacco nicotine extract product and an extraction technology for the same. The burley tobacco nicotine extract product is composed of the following components according to weight by percentage: 94 to 97% of nicotine, 0.4 to 0.6% of cotinine, 0.2 to 0.3% of N-methy pridine carboxamide, 0.1 to 0.2% of benzofuran, 0.1 to 0.2% of indol, 0.1 to 0.2% of 5.5-dimethyle pyrazoline, 0.05 to 0.15% of acetyl pridine, 0.05 to 0.1% of megastigmatrienone, 0.02 to 0.05% of hydroxide radical damascenone, 0.02 to 0.05% of palmitic acid and 0.01 to 0.04% of demethylation nicotine. The burley tobacco nicotine extract product has nigh nicotine content and has special flavor when prepared for electronic tobacco juice; electronic cigarette satisfaction can be enhanced; and the electronic cigarette can be closer to cigarette taste.

The invention provides a new nicotine-degrading bacteria-pseudomonas ZUTSKD and its application. The ZUTSKD (Pseudomonas sp.ZUTSKD) is stored in China Center for Type Culture Collection, the storing date was June 18th, 2007, the preservation no. is CCTCC NO:M 207083. The bacteria can degrade nicotine and generate such intermediate as 2, 3'-Bipyridine, cotinine, 3-(3, 4-dihydro-2H-pyrrol-5-y1)-Pyridine and 3-Pyridinecarboxylic acid, the max. nicotine concentration withstandable is 5.5 g/L. The invention can reduce the nicotine in waste cigarette residues, and is of certain application prospect in the industry.

The present invention relates to a multi portion intra-oral dosage form comprising at least one pharmaceutically active agent or health promoting agent wherein at least one portion comprises a component for creating a noticeable organoleptic sensation. Of certain interest is use of sensory markers/signals as conceptual aids for a subject using the dosage form whereby the organoleptic sensation/s is/are such that it/they facilitate/s for the subject to identify a portion and differentiate between different portions thereof. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N'-oxide, nornicotine, (S)-nicotine-N--glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms.

The invention discloses an application of melatonin in preparation of a medicine for improving oocyte quality. According to the invention, melatonin is directly added into an oocyte in-vitro maturation culture solution, which proves that the melatonin can relieve the reduction of the quality of the cotinine-induced oocytes and is shown as reduction of the ROS level in the oocytes, reduction of aneuploidy formation, promotion of uniform distribution of actin, improvement of the form of spindles and improvement of mitochondrial functions, and then the later fertilization rate of the oocytes is remarkably increased. The invention provides a method for improving the influence of the main metabolite cotinine of nicotine in the blood of a smoker on the quality of female oocytes, and provides aneffective method for improving the reproductive capacity of smoking women.

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

The invention discloses a method for evaluating the influences of smoking on the quality of oocytes. Specifically, oocytes are cultured to be mature in culture solutions containing different concentrations of cotinine. Finally, the influences of smoking on the quality of oocytes are evaluated by detecting some indicators, such as the maturation rate of oocytes, chromosomal aneuploidy, actin distribution, mitochondrial membrane potential, intracellular reactive oxygen species level, spindle morphology, chromosome arrangement of mature oocytes, sperm binding number after in-vitro fertilization,pronucleus formation rate after parthenogenetic activation and the like. Through a large number of objective tests, the influences of smoking on the quality of oocytes are evaluated, thus providing areference of theoretical data for the maintenance of reproductive capacity of female smokers.

The invention discloses a high-sensitivity and high-accuracy method for simultaneously determining NNAL and cotinine in urine. The method comprises the following steps: 1) preparing a single standardstock solution containing the NNAL, the cotinine, isotope-labeled NNAL and isotope-labeled cotinine; 2) preparing mixed standard sample working solutions having a series of concentrations and containing the NNAL and the cotinine, and making a standard curve; 3) taking a to-be-determined urine sample, adding a phosphate buffer solution containing an isotope-labeled internal standard, and adding 15-25 [mu]L of beta-glucuronidase for enzymolysis; and 4) taking out the sample solution subjected to the enzymolysis, naturally cooling the sample solution into the room temperature, performing solid-phase extraction, performing instrument analysis, and performing calculation according to the standard curve made in the step 2) to obtain the content of the NNAL and the cotinine. The method effectively solves the problems of complex pretreatment and long consumed time of an existing method for simultaneously testing the NNAL and the cotinine in the urine; and meanwhile, the matrix effect in the urine is greatly reduced, so that the detection sensitivity and accuracy are improved.

A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'-N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.

A composition suitable for use in a vaping device includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'- N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or solvents.

The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and/or reduced number of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.

The invention belongs to the field of tobacco products, and discloses a rose flavor smearing cigarette and a preparing method thereof. The rose flavor smearing cigarette is prepared from, by mass, 30-34% of paraffin, 21-25% of Vaseline, 2.0-2.5% of penetration enhancer, 7.0-8% of nicotine, 2.0-2.5% of cotinine, 3-3.5% of neophytadiene, 1.1-1.5% of furfural, 2.0-3% of quinoline, 0.6-0.8% of megastigmatrienone, 1.25-1.5% of geranylacetone and the like. Serving as substitute goods of a traditional cigarette, the rose flavor smearing cigarette has similar quality such as fragrance, strength and taste as the traditional cigarette. The rose flavor smearing cigarette is small in size, convenient to carry, free of combustion, capable of preventing a fire and wide in application range, does not affect surrounding people as no smoke is generated by the cigarette and avoids passive smoking.

The invention belongs to the field of cigarette products and discloses a cigarette with a mint flavor and a preparation method thereof. The cigarette with a mint flavor is made up of following ingredients such as paraffin, vaseline, propolis, nicotine, cotinine, neodiphene, furfural, violet alcohol, mezotone, geranyl acetone, catechol, dalcate, geranene, preservatives, sodium glycocholate, 5-hydroxymethyl furfural, ionone, purple yellow, mint flavor, the amount of pH regulators and the rest of stearic acid. The pH of the cigarette with a mint flavor ranges from 5.0 to 5.5. The cigarette with a mint flavor is used as a substitute for a conventional citrate and has the flavor, vigor and taste similar to the conventional one. The cigarette is convenient to carry and helps avoid fire disasters without combustion. People are not affected by smoke. Second-hand smoke is avoided. The cigratte has a broad application scope.

A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.

The invention discloses an ovulation detection test strip. The ovulation detection test strip comprises a PVC bottom plate, a sample pad, a gold label pad, a nitrocellulose film and a water absorption pad, wherein the nitrocellulose film is provided with a detection line T1, a detection line T2 and a quality control line, the detection line T1 is coated with a mouse anti-human beta LH monoclonal antibody 1A4, the detection line T2 is coated with a cotinine antigen, and the quality control line is coated with a goat anti-chicken IgY polyclonal antibody; and a colloidal gold mouse anti-human beta LH monoclonal antibody 6B8 conjugate, a colloidal gold chicken IgY antibody conjugate and a colloidal gold cotinine monoclonal antibody conjugate are cured on the gold label pad. The test strip is high in detection sensitivity and good in specificity, abnormal interpretation results caused by crossing of LH with follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH) can be avoided, detection results are more accurate, and monitoring of the smoking metabolite cotinine in urine is combined. The invention further discloses an ovulation detection method, the steps are simple, and the test result is accurate.